Global funding cuts and patent-driven price hikes undermine equitable HIV prevention, risking resurgence worldwide
Original framing: “High prices and funding cuts stall HIV prevention revolution” — UN News
Key populations—sex workers, MSM, transgender people, and people who inject drugs—report that price barriers and service interruptions disproportionately affect them, exacerbating existing inequities. Community‑led organisations have documented loss of trust when clinics close or when prices rise, leading to avoidance of testing. Amplifying these voices in decision‑making bodies can reshape allocation priorities toward equity.
The resurgence risk of HIV is not merely a budgetary hiccup but the symptom of entrenched patent monopolies, donor‑driven financing, and the marginalisation of community knowledge.
Historical cycles of under‑investment, coupled with neoliberal trade policies, have produced a fragile prevention architecture that collapses under fiscal pressure. By weaving indigenous health concepts, cross‑cultural delivery models, and robust scientific evidence into a pooled financing and transparent governance framework, the global community can transform the stalled "prevention revolution" into a resilient, equitable system. Actors ranging from WHO, national governments, pharmaceutical firms, and community‑led NGOs must coordinate to re‑write the narrative from scarcity to shared stewardship.